Johnson & Johnson Just Got a Big FDA Win
Yahoo Finance ·
Healthcare giant Johnson & Johnson ( JNJ -1.15% ) racked up another win this week from the U.S. Food and Drug Administration. The regulator approved JNJ's drug Imaavy to treat patients 12 and older who have a rare life-threatening condition called warm autoimmune hemolytic anemia (wAIHA), in which autoantibodies attack red blood cells, leading to severe anemia and fatigue. Between one and three new people per 100,000 are affected by wAIHA each year, and about 1 in 8,000 people live with the condition, according to JNJ. It's the second FDA win in as many months for JNJ. In July, the company won FDA approval for its dual-energy ablation catheter, which can deliver radiofrequency and pulsed field energy to treat atrial fibrillation, a common heart rhythm disorder.
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
353 participants
Related News
- Nvidia Crushes Earnings Estimates, Yet Crypto Traders Doubt $250 Finish by Month-End
- Cathie Wood Allocates 10 Percent of Portfolio to Elon Musk Ventures
- AstraZeneca's Tezspire Achieves Esophagitis Clinical Trial Goals
- Nvidia Posts $59.7 Billion Net Income in Q2 as Revenue Surges 106%
- Nvidia Reportedly Agrees to Acquire AI Platform Hugging Face for $12.9 Billion
- Stock Market Outlook: Will the S&P 500 Open Higher or Lower Today?
